Study of Metformin in Polycystic Ovarian Syndrome

Dr. Vinutha¹, Dr. Indirakumari² Dr. D. Vijaya³
1. Civil Assistant Surgeon, King George Hospital, Visakhapatnam
2. Associate Professor, Andhra Medical College, Visakhapatnam.
3. Gynaecologist Visakhapatnam

Abstract: Polycystic ovarian syndrome (PCOS) is a common hormonal disorder among women of reproductive age and is a leading cause of infertility. Insulin resistance and hyperinsulinemia play a key role in pathophysiology of PCOS. Recognition of hyperinsulinemia has led to the intervention of insulin sensitizing drugs to play a key role in the management of PCOS. Hence the present study was undertaken to measure the efficacy and safety of insulin sensitizing drug metformin in reversing the metabolic and endocrine disturbances in women with polycystic ovarian disease. Metformin 500 mg thrice daily was given until the cysts disappeared which was taken as the end point of the study. Follicular studies were done to check the effect of metformin on ovulation. Significance was tested by paired t test and p value calculated. Metformin was found effective in regressing polycystic changes in ovary, regularization of menstrual cycles and improving ovulatory cycles. The present study showed that metformin has a beneficial role in effective management of PCOS.

Keywords: Metformin, PCOS.

I. Introduction

Polycystic ovary syndrome (PCOS), also called hyperandrogenic anovulation (HA),¹ or Stein-Leventhal syndrome,² is one of the most common endocrine disorders among women. Symptoms and signs of PCOS are very heterogeneous. The disease presents with any of the following combination features like menstrual irregularities (irregular menstrual cycles, amenorrhea), signs of hyperandrogenism (hirsutism, acne, alopecia), a characteristic polycystic appearance of ovaries on ultrasound examination and endocrine disturbances involving high serum concentration of leutinizing hormones and androgens.

A link between disturbed insulin action and PCOS was first highlighted in 1980³ Insulin resistance and compensatory hyperinsulinemia play an important role in pathophysiology of PCOS. Insulin resistance is the lack of cellular sensitivity with respect to glucose metabolism.

The endocrine manifestations of hyperinsulinaemia are of hyperandrogenemia leading to anovulation, reproductive failure and skin stigmata (acne, alopecia, hirsutism). In addition hyperinsulinaemia is associated with metabolic disturbances like type 2 diabetes mellitus, dyslipidaemia, hypertension, and elevated plasma plasminogen activator-1 concentrations, all of which are risk factors for cardiovascular disease.

Regression of the symptoms of PCOS is achieved by reducing hyperinsulinaemia. Hence recognition of this hyperinsulinaemia has led to the intervention of insulin sensitizing drugs to play a key role in the management of PCOS. Among the available insulin sensitizing agents metformin is widely used due to its clinical trails with metformin have recorded a wide range of benefits⁴

II. Objectives

To study the efficacy and safety of metformin in regularization of menstrual cycles and regression of cysts in polycystic ovarian disease

III. Methodology

The study was performed on 57 women with PCOS in the out patient department of obstetrics and gynaecology, government general hospital, Guntur. Before starting the study the ethical committee approved the protocol. Written and informed consent was obtained from each patient.

Selection of patients: was done by standard diagnostic assessments:

1. History - taking specifically for menstrual pattern (oligomenorrhea, amenorrhea), features of hyperandrogenism (hirsutism, acne).
2. Gynaecologic ultrasonography - According to Rotterdam 12 or more follicles should be seen in an ovary on ultrasound examination. The follicles are oriented in the periphery giving the appearance of 'string of pearls'. Polycystic ovaries are defined as 12 or more follicles in at least 1 ovary measuring 2-9 mm volume of > 10 cm³

DOI: 10.9790/0853-14235054 www.iosrjournals.org 50 | Page
Study Of Metformin In Polycystic Ovarian Syndrome

3. Biochemical tests-

- Serum level of leutinizing hormone is elevated. The elevated level of LH:FSH ratio > 1.5-3 is an indicator of PCOS.
- Reversible estradiol :estrone ratio. Estrone level is markedly elevated in PCOS
- Sex hormone binding globulin is elevated in PCOS
- Adrostenedione is elevated.
- 2-Hour oral glucose tolerance test (GTT) in women with risk factors (obesity, family history, history of gestational diabetes) may indicate impaired glucose tolerance (insulin resistance) in 15–33% of women with PCOS. Frank diabetes can be seen in 65–68% of women with this condition. Insulin resistance can be observed in both normal weight and overweight people.

50–80% of people with PCOS may have insulin resistance at some level.

Inclusion criteria:
1. Age: 15-30 yrs
2. Women with irregular menstrual cycles and evidence of polycystic ovaries on ultrasound

Exclusion criteria:
Other causes of chronic anovulation
1. Hyperprolactinemia
2. Hypothyroidism
3. Congenital adrenal hyperplasia

Procedure: 57 women who had polycystic ovaries on ultrasound were selected for the study. Detailed menstrual history regarding age of menarche, menstrual cycle and period of infertility were obtained from every patient. Each patient was questioned about past and family history of diabetes mellitus and hypertension. Body weight and height were estimated to calculate body mass index. Clinical examination with special reference to hirsutism was done. Investigations like ultrasound, fasting blood glucose, and thyroid stimulating hormone levels were done. Among 57 women seven women discontinued due to incompliance. So 50 women were taken into study. These 50 women were given metformin 500mg once daily for one week, followed by twice daily in the second week, and then thrice daily from third week to avoid incompliance. Ultrasound examination was done every month to note the disappearance of cysts and evidence of ovulation was seen by follicular study from day 11 to day 21 alternately. Results were tabulated, significance was tested by paired t test and p values. Results were shown graphically also.

IV. Results

Metformin was well tolerated by all patients. Among 50 patients 18 patients were between 15-25 yrs and 32 patients were between 26-32 yrs. So the incidence of PCOS is more at the age of 15-25 yrs.

Body Mass Index: The BMI mean±(SD) before treatment was 26.42kg/m²±(2.52) and after treatment it reduced to 25.1kg/m²±(2.59)(p>0.05).
Menstrual Cycles: Among 50 (100%) patients who had irregular periods, 44%(88%) patients showed improvement in menstrual cycles.

<table>
<thead>
<tr>
<th>MENSTRUAL CYCLES</th>
<th>BEFORE TREATMENT</th>
<th>AFTER TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irregular</td>
<td>50</td>
<td>6</td>
</tr>
<tr>
<td>Regular</td>
<td>0</td>
<td>44</td>
</tr>
</tbody>
</table>

Ovulation: Among 50 patients ovulation was seen in 39 (78%) patients at the end of the first month out of 50 patients ovulation was seen in 3 patients at the end of the second month out of 47 patients ovulation was seen in 22 patients at the end of the third month out of 25 patients ovulation was seen in 9 patients. At the end of 4th month out of 16 patients ovulation was seen in 5 patients. In the 11 patients there was no ovulation at the end of 6 months.

<table>
<thead>
<tr>
<th>Ovulation</th>
<th>Before treatment</th>
<th>After treatment</th>
<th>Total number of patients at the end of the study (n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovulation absent</td>
<td>50</td>
<td>47</td>
<td>11</td>
</tr>
<tr>
<td>Ovulation present</td>
<td>0</td>
<td>3</td>
<td>11</td>
</tr>
<tr>
<td>Total</td>
<td>50</td>
<td>47</td>
<td>22</td>
</tr>
</tbody>
</table>
Cysts: Among 50 patients 41 patients (82%) patients showed disappearance of cysts. At the end of 1st month out of 50 patients cysts disappeared in 3 patients. At the end of 2nd month out of 47 patients cysts disappeared in 23 patients. At the end of 3rd month out of 24 patients cyst disappeared in 11 patients. At the end of 4th month out of 13 patients cyst disappeared in 4 patients. In patients cyst did not disappear at the end of 6 month.

<table>
<thead>
<tr>
<th></th>
<th>Before treatment</th>
<th>After treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=50)</td>
<td></td>
</tr>
<tr>
<td>Cyst present</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyst absent</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fasting Blood Glucose: The fasting blood glucose mean±(SD) before treatment was 88.56 mg/dl ±(8.59) and after treatment it reduced to 79.58 mg/dl ±(6.92)(p<0.001, highly significant).

**MEAN FASTING BLOOD GLUCOSE**

<table>
<thead>
<tr>
<th>Fasting blood glucose (mg/dl)</th>
<th>Before treatment</th>
<th>After treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean±SD</td>
<td>88.56±8.59</td>
<td>79.6±6.92</td>
</tr>
</tbody>
</table>

V. Discussion

The results in the present study suggested that metformin has an effective role in the management of PCOS. In the study metformin improved the regularization of menstrual cycles in 88% of previously amenorrheic women with PCOS. These results were consistent with those of Glueck, C.J., Wang, P., Fontaine, R., et al [5] who concluded in their study that metformin resumed normal menses in 91% of previously amenorrheic women.

The cycles became ovulatory after metformin treatment in 78% women with previous anovulatory cycles. These results were consistent with that of Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., et al [6] who concluded in their study that metformin showed 79% improvement in ovulation.

In their study they concluded that metformin showed 79% improvement in ovulation. The above results show that metformin had a promising role with regression of polycystic ovarian
changes, regularization of menstrual cycles and resumption of ovulation in the management of PCOS.

VI. Conclusion

Insulin resistance plays a key role in the pathogenesis of PCOS, altering the endocrine and metabolic disturbances. In this regard, insulin sensitizing drugs like metformin show promising results in reversing this endocrinopathy and improvement in the metabolic disturbances. 50 patients were recruited in the study. Metformin 500mg thrice daily was given until the cysts disappeared which was taken as the end point of the study. Follicular studies were done to check the effect of metformin on ovulation. Significance was tested by paired t test and the p value was calculated. Results were represented graphically.

Metformin was found to be effective in regressing polycystic changes in ovary, regularization of menstrual cycles and improving ovulatory cycles.

In conclusion, metformin has a beneficial role in the management of PCOS.

References


[2]. "USMLE-Rx". MedIQ Learning, LLC. 2014. Stein-Leventhal syndrome, also known as polycystic ovary syndrome (PCOS), is a disorder characterized by hirsutism, obesity, and amenorrhea because of luteinizing hormone-resistant cystic ovaries.


